Ikena Oncology Inc (IKNA) Actualités

Form ARS - Annual Report to Security Holders

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 425 - Prospectuses and communications, business combinations

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Ikena Oncology Reports Third Quarter 2024 Financial Results

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Ikena Oncology Reports Second Quarter 2024 Financial Results

BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

UPDATE – Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers;...